Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Year: 1999
Type: article
Study design: Clinical Trial
Source: PubMed
Authors: M E Juweid, E Stadtmauer, G Hajjar, R M Sharkey, S Suleiman, S Luger, L C Swayne, A Alavi, D M Goldenberg
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W2118833600